Inhaler Devices: The past, the Present, and the Future

This symposium took place on 27th September 2015, as part of the European Respiratory Society International Congress 2015 in Amsterdam, Netherlands

Chairperson: Richard Dekhuijzen1
Speakers: Gary Wong,2 J. Christian Virchow,3 Henry Chrystyn4-6

1. Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands
2. Department of Paediatrics and School of Public Health, Chinese University of Hong Kong, Hong Kong
3. Department of Pneumology/Intensive Care Medicine, Medizinische Klinik 1, Zentrum für Innere Medizin, Universitätsmedizin Rostock, Rostock, Germany
4. Talmedica Ltd., St Crispin House, Haslingden, UK
5. Faculty of Health and Human Sciences, University of Plymouth, Plymouth, UK
6. Research in Real Life (RiRL), Cambridge, UK

Disclosures: Richard Dekhuijzen and/or his department have received research grants, unrestricted educational grants, and/or fees for lectures and advisory board meetings from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Takeda, Teva Pharmaceuticals, and Zambon. Gary Wong has received research grants from the European Commission, National Natural Science Federation of China, and both the Research Grants Council and Health and Medical Research Fund of Hong Kong. He is also on the advisory board for, and has received industrial grants and travel grants from MSD, GlaxoSmithKline, Pfizer, Takeda, Danone, Nestlé, Mundipharma, AstraZeneca, and Roche. J. Christian Virchow has lectured for and received honoraria from Allergopharma, ALK, Asche-Chiesi, AstraZeneca, Avontec, Bayer, Bencard, Berlin-Chemie, Bionorica, Boehringer Ingelheim, Essex/ScheringPlough, GlaxoSmithKline, Janssen-Cilag, Kyorin, Leti, MEDA, Merck/MSD, Mundipharma, Novartis, Nycomed/ Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, Takeda, Teva Pharmaceuticals, UCB/Schwarz-Pharma, and Zydus/Cadila. He has participated in advisory boards for ALK, Asche-Chiesi, Avontec, Berlin-Chemie, Boehringer Ingelheim, Essex/Schering-Plough, GlaxoSmithKline, Janssen-Cilag, MSD/Merck, Mundipharma, Novartis, Revotar, Sandoz-Hexal, UCB/Schwarz-Pharma, and Takeda. He has received grants from Deutsche Forschungsgemeinschaft, Land Mecklenburg-Vorpommern, GlaxoSmithKline, and MSD. Henry Chrystyn has no shares in any pharmaceutical companies. He has received sponsorship, consultancy agreements, and honoraria for presentations from several pharmaceutical companies that market inhaled products, including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Mundipharma, Napp Pharmaceuticals, NorPharma, Orion, Sanofi, Teva Pharmaceuticals, Truddell Medical International, UCB, and Zentiva. He has also received research sponsorship from the grant-awarding bodies Engineering and Physical Sciences Research Council and Medical Research Council.
Acknowledgements: Writing assistance was provided by Dr Sarah Utley, ApotheCom.
Support: The publication of this article was funded by Teva Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Teva Pharmaceuticals.
Citation: EMJ Respir. 2015;3[2]:49-54.

Meeting Summary

Inhaler handling errors negatively impact asthma control and represent one of the most common challenges in asthma management. Overcoming inhaler handling errors can be achieved by increased awareness of errors, more explicit and consistent training in inhaler use, and development of ‘intuitive’ devices. Clinical studies have shown that dry powder inhalers (DPIs) have better dose consistency and delivery to the lungs, but this is also dependent on device and inhalation technique. In addition, recent clinical studies have demonstrated that Spiromax® is a more intuitive device than Turbuhaler®. In studies analysing patient device mastery, intuitive devices are preferred by patients because they are easy/simple to use and have effective dose delivery.

Download (PDF, 104KB)

Comments are closed.